Biology Atlas

Map / Drugs

drug · intermediate · partly written

Holoclar

Holoclar is a patient's own limbal stem cells, grown on a fibrin carrier and placed on the burned eye to rebuild the surface of the cornea.

Also called: autologous cultured limbal stem cells

This describes published medicine for readers who want to understand how it works and what happened. It is not medical advice and says nothing about what any person should take.

What it is

A patient's own corneal stem cells, taken as a tiny biopsy from a healthy part of the eye, multiplied in a laboratory on a fibrin sheet, and put back on the burned eye by a surgeon. It is made for one patient only and cannot be given to anyone else. 1

Reported, not yet replicated

How it is made and placed more

A piece of healthy limbus of 1-2 mm2 is taken in hospital and sent to the manufacturer. The cells are grown, frozen until surgery is scheduled, then thawed and grown on a fibrin membrane (fibrin is the clotting protein, here a carrier). The product goes back to the hospital and is implanted at once; antibiotics and an anti-inflammatory medicine are given afterwards. It is intended as a single treatment, repeatable if a doctor considers it necessary.

There is no separate glue step to explain: the surgeon places a sheet on a flat surface, and the cells stay because they are the right cell type in a tissue that renews itself. 1

Reported, not yet replicated

Why it is not rejected more

The EMA states it may be given only to the patient whose own limbal cells were used to make it. Cells carrying your own HLA tags are not foreign to your immune system, so the immune suppression that donor cell therapies need is not part of this one. An autologous product is compatible with the recipient by construction. 12

Reported, not yet replicated

The evidence and how much to trust it deep

1997: two patients with severe alkali burns received cultured autologous epithelium grown from a 1 mm2 limbal biopsy of the healthy eye and were followed for more than 2 years.

2010: 112 patients treated with autologous limbal stem cells on fibrin; permanent restoration of a transparent, renewing corneal epithelium in 76.6 percent of eyes, failures within the first year, follow-up up to 10 years but mean 2.91 and median 1.93 years, so most follow-up is short. In post hoc analysis, cultures with more than 3 percent p63-bright cells succeeded in 78 percent and the rest in 11 percent.

Regulator: the retrospective study judged 75 of 104 patients (72 percent) successful at one year (stable surface, no defects, little or no ingrown vessels).

Prospective check (HOLOCORE, open-label, single arm, 80 started, 49 completed): successful transplantation at 12 months in 36.2 percent (n=69, 95% CI 25 to 49), and 33.8 percent (n=65, 95% CI 23 to 47) in the second analysis set. All of these are uncontrolled, so surgery and natural recovery cannot be separated from the product. 3415

Reported, not yet replicated

Modality

Stem cell therapy

Targets

Pathways

Indications

Identifiers

Eudract holocore

2014-002845-23

Ema epar page

Holoclar

Mechanism

The cornea's outer skin is renewed by stem cells in a ring at its edge, the limbus. A burn can destroy them, and conjunctival cells then grow over the cornea with scar and blood vessels. A small piece of healthy limbus (1-2 mm2) is taken from the patient, the cells are grown in the laboratory and then on a fibrin membrane, and a trained eye surgeon implants the result on the damaged eye. Because stem cells, and not only surface cells, are put back, the epithelium can keep renewing itself. 134

Reported, not yet replicated

Delivery route

Must survive

Not the blood or the gut: the cells are made outside the body and placed directly on the eye, so the hurdles are manufacturing and take. The label requires at least 1-2 mm2 of undamaged limbus to start from, so a patient with none is outside it. The cultures must contain enough true stem cells: in the 2010 case series, success was associated with the share of p63-bright stem cells in the culture (more than 3 percent: 78 percent success; 3 percent or less: 11 percent), but that was a post hoc analysis. 14

Reported, not yet replicated

Assays used

p63-bright stem-cell fraction of the culture

Rama and colleagues counted the share of cells staining intensely for p63 (a marker of holoclone-forming stem cells) and related it to outcome after the fact. 4

Reported, not yet replicated

Side effects

Common side effects

The EMA page lists eye pain, corneal epithelial defects, conjunctival haemorrhage and blepharitis as common (up to 1 in 10 people). 1

Reported, not yet replicated

Serious adverse events in the prospective study

In HOLOCORE, serious adverse events occurred in 12 of 76 adults (15.8 percent) and 0 of 4 children, with no deaths. 5

Reported, not yet replicated

Verdict

Outcome

worked

Why

It reached full EU marketing authorisation (conditional in 2015, standard in 2024), and the evidence is graded rather than absolute. A retrospective study of 104 patients judged 75 (72 percent) successful at one year, and a case series of 112 patients reported permanent restoration of the corneal epithelium in 76.6 percent of eyes. The prospective single-arm HOLOCORE study gave a lower primary result, 36.2 percent (95% CI 25 to 49) at 12 months in 69 patients. The records read here do not explain the gap; different definitions of success and retrospective versus prospective design are candidates, which is our reasoning and not a finding. Part of why it works is that the cells are the patient's own, so there is nothing foreign to reject. 145

Reported, not yet replicated

Failure mode

Not a failure, but where it falls short: in the 2010 case series the failures occurred within the first year, and in the prospective study 49 of the 80 who started completed it. Cultures low in stem cells did badly in the post hoc analysis. 45

Reported, not yet replicated

Teach this

In one sentence

Holoclar works because it rebuilds a thin, flat tissue from the patient's own stem cells, so neither rejection nor wiring is a problem. 1

Reported, not yet replicated

The five-minute version

The cornea's surface is renewed by stem cells at the limbus. A burn can kill them. Take a 1-2 mm2 biopsy from a healthy part, grow the cells on fibrin, put the sheet on the damaged eye. Own cells mean no rejection. Success rates differ by study, 72 percent retrospective and 36 percent prospective, so say which one you mean. 15

Reported, not yet replicated

What a listener will ask

Is it a transplant from a donor?

No. It is made from the patient's own cells and may be given only to that patient.

Why do two studies give 72 and 36 percent?

Different design (retrospective versus prospective) and success definitions are candidates; the sources opened do not settle it.

The common wrong idea

A cell therapy that works shows that replacing cells in general works.

This works for a thin, flat, self-renewing surface where a few cells do a structural job, using the patient's own cells; deep brain circuits and donor cells are different problems.

The one citation to hand over: 1

Still open here

Not yet written: Off targets.

Linked from

Sources

  1. European Medicines Agency. Holoclar: European public assessment report summary page. EMA (2024). regulatory, not peer reviewed; opened 2026-11-17 all records citing this
  2. Flahou, C., Morishima, T., Takizawa, H., et al.. Fit-for-all iPSC-derived cell therapies and their evaluation in humanized mice with NK cell immunity. Frontiers in Immunology (2021). review; opened 2026-11-17 all records citing this
  3. Pellegrini, G., Traverso, C. E., Franzi, A. T., et al.. Long-term restoration of damaged corneal surfaces with autologous cultivated corneal epithelium. The Lancet (1997). paper; opened 2026-11-17 all records citing this
  4. Rama, P., Matuska, S., Paganoni, G., et al.. Limbal stem-cell therapy and long-term corneal regeneration. New England Journal of Medicine (2010). paper; opened 2026-11-17 all records citing this
  5. Holostem Terapie Avanzate s.r.l. (sponsor). EU Clinical Trials Register: results for EudraCT 2014-002845-23 (HOLOCORE). EU Clinical Trials Register. database, not peer reviewed; opened 2026-11-17 all records citing this
History of this record (1)

This record has been changed 1 time, on the dates below. The note kept against each change is written for the people who maintain the atlas, in their own shorthand, so it is not shown here; it is in the record itself.

Year
2015
Regulatory status
approved
Status
partly written
Last updated
2026-11-17
Record
content/drugs/holoclar.json